文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

血浆可溶性CD14亚型水平与重症COVID-19患者临床结局相关

Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019.
PubMed 文献 · Crit Care Explor · 2021-12-09
一句话结论重症COVID-19患者入院血浆可溶性CD14亚型较非COVID-19患者低54%,但无论COVID-19状态,较高水平均与死亡、休克及更少无呼吸机天数相关。

这项前瞻性队列研究纳入西雅图三家三级医院ICU的204例疑似COVID-19危重患者,其中102例确诊COVID-19、102例非COVID-19,入院时检测血浆可溶性CD14及可溶性CD14亚型。校正年龄、性别、种族/民族、激素治疗、合并症及病情严重度后,COVID-19患者可溶性CD14亚型较非COVID-19患者低54%(倍数差异0.46,95%CI 0.28-0.77,p=0.003),而可溶性CD14两组无差异。在COVID-19与非COVID-19两组中,校正年龄、性别、种族/民族、激素治疗及合并症后,较高可溶性CD14亚型均与死亡相关(COVID-19:校正相对危险度1.21,95%CI 1.06-1.39,p=0.006;非COVID-19:校正相对危险度1.19,95%CI 1.03-1.38,p=0.017),并与休克及更少无呼吸机天数相关。仅在COVID-19患者中,可溶性CD14亚型升高与严重急性肾损伤相关(校正相对危险度1.23,95%CI 1.05-1.44,p=0.013)。作者认为可溶性CD14亚型可能对COVID-19具有预后价值。

要点

  • 在204例ICU疑似COVID-19患者中,校正混杂因素后COVID-19患者可溶性CD14亚型较非COVID-19患者低54%(倍数差异0.46,95%CI 0.28-0.77,p=0.003)。
  • 无论是否COVID-19,校正后较高可溶性CD14亚型均与死亡相关:COVID-19校正相对危险度1.21(95%CI 1.06-1.39,p=0.006),非COVID-19校正相对危险度1.19(95%CI 1.03-1.38,p=0.017)。
  • 较高可溶性CD14亚型在两组中均与休克及更少无呼吸机天数相关。
  • 仅在COVID-19患者中,可溶性CD14亚型升高与严重急性肾损伤相关(校正相对危险度1.23,95%CI 1.05-1.44,p=0.013)。
  • 可溶性CD14水平在COVID-19与非COVID-19患者间无差异。

适用人群与场景

  • 西雅图三家三级医院ICU收治的204例疑似COVID-19危重患者,入院时采集血样。
  • 共204例,其中102例确诊COVID-19、102例非COVID-19;两组最常见ICU入住诊断为呼吸衰竭或肺炎,入院时接受呼吸支持的比例相似。

研究设计与关键结果

  • 研究设计:前瞻性队列研究,纳入西雅图三家三级医院ICU的204例疑似COVID-19危重患者,入院时检测血浆可溶性CD14及可溶性CD14亚型。
  • COVID-19状态与生物标志物:校正年龄、性别、种族/民族、激素治疗、合并症及病情严重度后,可溶性CD14亚型在COVID-19患者较非COVID-19患者低54%(倍数差异0.46,95%CI 0.28-0.77,p=0.003);可溶性CD14水平两组无差异。
  • 结局关联:在COVID-19与非COVID-19两组中,校正年龄、性别、种族/民族、激素治疗及合并症后,较高可溶性CD14亚型与死亡相关(COVID-19:校正相对危险度1.21,95%CI 1.06-1.39,p=0.006;非COVID-19:校正相对危险度1.19,95%CI 1.03-1.38,p=0.017),并与休克及更少无呼吸机天数相关。
  • 仅在COVID-19患者中,可溶性CD14亚型升高与严重急性肾损伤相关(校正相对危险度1.23,95%CI 1.05-1.44,p=0.013)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 作者结论:较高血浆可溶性CD14亚型与危重患者更差临床结局相关,无论COVID-19状态;可溶性CD14亚型水平可能对COVID-19具有预后价值。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为可溶性CD14亚型可能对COVID-19具有预后价值;该标志物为入院单次检测,尚不能据此给出床旁决策建议。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In bacterial sepsis, CD14 and its N-terminal fragment (soluble CD14 subtype, "Presepsin") have been characterized as markers of innate immune responses and emerging evidence has linked both to coronavirus disease 2019 pathophysiology.

OBJECTIVES: Our aim was to determine the relationship between the soluble form of CD14 and soluble CD14 subtype plasma levels, coronavirus disease 2019 status, and coronavirus disease 2019-related outcomes.

DESIGN: A prospective cohort study.

SETTING: ICUs in three tertiary hospitals in Seattle, WA.

PARTICIPANTS: Two-hundred four critically ill patients under investigation for coronavirus disease 2019.

MAIN OUTCOMES AND MEASURES: We measured plasma soluble CD14 and soluble CD14 subtype levels in samples collected upon admission. We tested for associations between biomarker levels and coronavirus disease 2019 status. We stratified by coronavirus disease 2019 status and tested for associations between biomarker levels and outcomes.

RESULTS: Among 204 patients, 102 patients had coronavirus disease 2019 and 102 patients did not. In both groups, the most common ICU admission diagnosis was respiratory failure or pneumonia and proportions receiving respiratory support at admission were similar. In regression analyses adjusting for age, sex, race/ethnicity, steroid therapy, comorbidities, and severity of illness, soluble CD14 subtype was 54% lower in coronavirus disease 2019 than noncoronavirus disease 2019 patients (fold difference, 0.46; 95% CI, 0.28-0.77; p = 0.003). In contrast to soluble CD14 subtype, soluble CD14 levels did not differ between coronavirus disease 2019 and noncoronavirus disease 2019 patients. In both coronavirus disease 2019 and noncoronavirus disease 2019, in analyses adjusting for age, sex, race/ethnicity, steroid therapy, and comorbidities, higher soluble CD14 subtype levels were associated with death (coronavirus disease 2019: adjusted relative risk, 1.21; 95% CI, 1.06-1.39; p = 0.006 and noncoronavirus disease 2019: adjusted relative risk, 1.19; 95% CI, 1.03-1.38; p = 0.017), shock, and fewer ventilator-free days. In coronavirus disease 2019 only, an increase in soluble CD14 subtype was associated with severe acute kidney injury (adjusted relative risk, 1.23; 95% CI, 1.05-1.44; p = 0.013).

CONCLUSIONS: Higher plasma soluble CD14 subtype is associated with worse clinical outcomes in critically ill patients irrespective of coronavirus disease 2019 status though soluble CD14 subtype levels were lower in coronavirus disease 2019 patients than noncoronavirus disease 2019 patients. Soluble CD14 subtype levels may have prognostic utility in coronavirus disease 2019.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Mabrey FL, Morrell ED, Bhatraju PK, et al. Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019. Crit Care Explor. 2021. PMID: 34909698. doi:10.1097/CCE.0000000000000591

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。